{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-002873","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.141595+00:00","generated_at":"2026-05-28T02:52:49.035454+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CVRx reports Q4 2024 preliminary revenue $15.2-15.3M (+35% YoY), issues FY2025 guidance $63-65M","bullets":["Q4 2024 revenue $15.2–15.3M, up 35% from $11.3M; U.S. $14.2–14.3M, Europe $1.0M.","FY2024 revenue $51.1–51.2M (+30% YoY); U.S. $47.0–47.1M, Europe $4.1M.","FY2025 guidance: revenue $63–65M (23–27% growth), gross margin 83–84%, opex $100–104M.","Q1 2025 revenue guidance $14.5–15.0M.","Active U.S. implanting centers 223 (up from 208); cash $105.9M; ATM raised $12.8M via 869K shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-002873","json":"https://secwatch.observer/filing/0001104659-25-002873.json","markdown":"https://secwatch.observer/filing/0001104659-25-002873.md","text":"https://secwatch.observer/filing/0001104659-25-002873.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465925002873/0001104659-25-002873-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465925002873/tm253027d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:52:49.035454+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}